Halozyme Therapeutics (NASDAQ:HALO) investors had a great day today, with the stock up 12% on the news that the FDA lifted a clinical hold on its phase 2 trial of PEGPH20 for pancreatic cancer.
The hold had reflected FDA concerns about potential blood clots, but some changes to the trial design and screening sufficiently allayed those fears to allow the trial to proceed, and Halozyme has announced that it plans to enroll additional patients.
In this video, from Thursday's Market Checkup, the Motley Fool's health care-focused investing show, analysts Michael Douglass and David Williamson discuss the changes to the trial and what they think of the stock.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Google Gaining Ground in the Battle for Smart Homes
Amazon's Alexa is the leader for now, but Google has a lot going for it.
Here's How Intel Corporation Crushed It in 2017
It was a breakout year in many ways for the data center first provider, and it’s just the beginning of what’s to come.
3 Things You Can Do This Year to Increase Your Social Security Benefits
Want more money out of Social Security? Here's how to get it.